Accuray 배당금 및 환매

배당금 기준 확인 0/6

Accuray 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

-1.2%

환매 수익률

총 주주 수익률	-1.2%
미래 배당 수익률	n/a
배당금 성장	n/a
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
지급 비율	n/a

최근 배당금 및 환매 업데이트

업데이트 없음

Recent updates

Accuray Remains A Perpetual 'Next Year Is Our Year' Story

Aug 18

Accuray Incorporated's (NASDAQ:ARAY) 28% Dip In Price Shows Sentiment Is Matching Revenues

Aug 13

Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 25% Price Drop

May 21

Analysts Have Lowered Expectations For Accuray Incorporated (NASDAQ:ARAY) After Its Latest Results

May 04

Why Investors Shouldn't Be Surprised By Accuray Incorporated's (NASDAQ:ARAY) 26% Share Price Plunge

Aug 17

These 4 Measures Indicate That Accuray (NASDAQ:ARAY) Is Using Debt Extensively

Apr 13

The Return Trends At Accuray (NASDAQ:ARAY) Look Promising

Mar 14

Accuray (NASDAQ:ARAY) Takes On Some Risk With Its Use Of Debt

Dec 01

Accuray (NASDAQ:ARAY) Is Doing The Right Things To Multiply Its Share Price

Oct 27

Accuray launches CyberKnife platform in Africa for cancer patients

Sep 30

Accuray GAAP EPS of -$0.04 beats by $0.03, revenue of $110.02M beats by $4.7M

Aug 10

Here's Why Accuray (NASDAQ:ARAY) Has A Meaningful Debt Burden

Jul 08

Accuray (NASDAQ:ARAY) Might Have The Makings Of A Multi-Bagger

Jun 15

Accuray: Nothing Special

May 31

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 ARAY 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: ARAY 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Accuray 시장 대비 배당 수익률

ARAY 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (ARAY)	n/a
시장 하위 25% (US)	1.4%
시장 상위 25% (US)	4.3%
업계 평균 (Medical Equipment)	1.6%
애널리스트 예측 (ARAY) (최대 3년)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ARAY 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ARAY 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ARAY 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: ARAY 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Accuray 배당금 및 환매

배당금 기준 확인 0/6

주요 정보

최근 배당금 및 환매 업데이트

Recent updates

Accuray Incorporated Raises Financial Guidance for the Fiscal Year Ending June 30, 2025

Accuray Incorporated to Report Q1, 2025 Results on Nov 06, 2024

Accuray Incorporated Announces CEO Changes

Accuray Incorporated, Annual General Meeting, Nov 21, 2024

Accuray Incorporated announced delayed annual 10-K filing

Accuray Incorporated President Suzanne Winter to Take Temporary Medical Leave of Absence

Accuray Remains A Perpetual 'Next Year Is Our Year' Story

Forecast breakeven date pushed back to 2026

New major risk - Share price stability

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Accuray Incorporated Provides Earnings Guidance for the Fiscal Year 2025

Accuray Incorporated's (NASDAQ:ARAY) 28% Dip In Price Shows Sentiment Is Matching Revenues

Accuray Incorporated to Report Q4, 2024 Results on Aug 14, 2024

Accuray Incorporated Announces Approval of the Accuray Precision Treatment Planning System by China's National Medical Products Administration

Forecast breakeven date pushed back to 2026

Independent Chairman of the Board recently bought US$156k worth of stock

Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 25% Price Drop

Accuray Incorporated Announces Executive Changes, Effective May 17, 2024

Analysts Have Lowered Expectations For Accuray Incorporated (NASDAQ:ARAY) After Its Latest Results

Price target decreased by 11% to US$7.75

Are Investors Undervaluing Accuray Incorporated (NASDAQ:ARAY) By 25%?

Accuray Incorporated Provides Earnings Guidance for the Year 2024

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Now 35% undervalued after recent price drop

Accuray Incorporated Showcases Advances in Radiation Therapy Solutions Designed to Improve the Cancer Treatment Experience at ESTRO 2024

Accuray Incorporated to Report Q3, 2024 Results on May 01, 2024

Accuray Getting Very Little Love Ahead Of A Coming Revenue Ramp

Accuray Incorporated Announces New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can Be Effectively Treated in 5 Days Using the Accuray CyberKnife System

New minor risk - Shareholder dilution

Is Accuray (NASDAQ:ARAY) A Risky Investment?

Second quarter 2024 earnings: EPS misses analyst expectations

Accuray Incorporated Reaffirms Revenue Guidance for the Third Quarter and Full Fiscal Year 2024

Accuray Incorporated to Report Q2, 2024 Results on Jan 31, 2024

President recently sold US$162k worth of stock

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

President recently sold US$99k worth of stock

Accuray Incorporated to Report Q1, 2024 Results on Nov 07, 2023

Accuray Announces Approval of the Tomo C Radiation Treatment Delivery System by China's National Medical Products Administration

Accuray Incorporated, Annual General Meeting, Nov 09, 2023

Why Investors Shouldn't Be Surprised By Accuray Incorporated's (NASDAQ:ARAY) 26% Share Price Plunge

Full year 2023 earnings: EPS misses analyst expectations

Forecast breakeven date pushed back to 2025

Accuray Incorporated Provides Revenue Guidance for Fiscal Year 2024

Accuray Incorporated to Report Q4, 2023 Results on Aug 09, 2023

President recently sold US$65k worth of stock

Insider recently sold US$93k worth of stock

Accuray Incorporated Announces New Data Presented at the European Society for Radiotherapy and Oncology

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

These 4 Measures Indicate That Accuray (NASDAQ:ARAY) Is Using Debt Extensively

The Return Trends At Accuray (NASDAQ:ARAY) Look Promising

Accuray Incorporated Announces Data from Randomized, Multicenter Trial PACE-A

High number of new directors

Accuray Incorporated Reiterates Earnings Guidance for the Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Accuray Incorporated Announces the Appointment of Robert C. Kill to its Board of Directors

Accuray Incorporated to Report Q2, 2023 Results on Feb 01, 2023

Accuray Incorporated Announces First Patient Treatments in New Zealand with the CyberKnife(R) System

Accuray Incorporated Announces Intent to Resign from Position as Chief Accounting Officer and Principal Accounting Officer, Effective January 3, 2023

Accuray (NASDAQ:ARAY) Takes On Some Risk With Its Use Of Debt

First quarter 2023 earnings: EPS and revenues miss analyst expectations

President recently sold US$76k worth of stock

Accuray Incorporated Re-Affirms Guidance for Year 2023

Accuray Announces Tomo C Registration Submission to China's National Medical Products Administration

High number of new directors

Accuray (NASDAQ:ARAY) Is Doing The Right Things To Multiply Its Share Price

Japanese Ministry of Health, Labor and Welfare Approves Reimbursement for the Cyberknife(R) System for the Treatment of Trigeminal Neuralgia

Accuray Incorporated to Report Q1, 2023 Results on Nov 02, 2022

Accuray Incorporated Announces Data Published in The Lancet Oncology Indicate Men With Prostate Cancer Treated With the Accuray CyberKnife® Platform Experienced a Lower Incidence of Bladder Side Effects Than Those Treated With Conventional Linear Accelerators

Accuray Incorporated, Annual General Meeting, Nov 10, 2022

Accuray launches CyberKnife platform in Africa for cancer patients

Richard R. Pettingill Not to Stand for Re-Election as Class I Director of Accuray Incorporated

Accuray Incorporated Appoints Seth Blacksburg as Chief Medical Officer

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Accuray Incorporated Provides Revenue Guidance for Year 2023

Accuray GAAP EPS of -$0.04 beats by $0.03, revenue of $110.02M beats by $4.7M